Takeda Pharmaceutical Co. Ltd. (TAK) intrinsic value & 10-year financials
Takeda Pharmaceutical Co. Ltd. (TAK) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 12.9% a year to ¥4.6T, with an average return on invested capital of 3.6%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- ¥4.6T
- Revenue growth (10-yr CAGR)
- 12.9%
- ROIC (10-yr avg)
- 3.6%
- Free cash flow (FY2025)
- ¥856.4B
TAK 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | ¥4.6T | ¥108.1B | ¥67.23 | ¥856.4B | 7.5% | 1.9% |
| FY2024 | ¥4.3T | ¥144.2B | ¥91.16 | ¥540.9B | 5.0% | 2.0% |
| FY2023 | ¥4.0T | ¥317.0B | ¥201.94 | ¥836.5B | 12.2% | 4.3% |
| FY2022 | ¥3.6T | ¥230.2B | ¥145.87 | ¥999.9B | 12.9% | 3.9% |
| FY2021 | ¥3.2T | ¥376.2B | ¥238.96 | ¥899.7B | 15.9% | 5.6% |
| FY2020 | ¥3.3T | ¥44.3B | ¥28.25 | ¥542.7B | 3.1% | 0.5% |
| FY2019 | ¥2.1T | ¥109.0B | ¥112.86 | ¥250.8B | 9.8% | 3.2% |
| FY2018 | ¥1.8T | ¥186.7B | ¥237.56 | ¥310.8B | 13.7% | 7.7% |
| FY2017 | ¥1.7T | ¥115.5B | ¥146.26 | ¥199.7B | 9.0% | — |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in JPY.
Executive summary
TAKEDA PHARMACEUTICAL CO LTD revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
TAKEDA PHARMACEUTICAL CO LTD has historically struggled to out-earn its cost of capital, averaging just 3.6% ROIC.
TAKEDA PHARMACEUTICAL CO LTD capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, TAKEDA PHARMACEUTICAL CO LTD is modeled at -9.3% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-581.18 per share.